NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Castle Creek Biosciences

Castle Creek Biosciences

Private
Exton, PennsylvaniaHealthcare & Life Scienceshttps://castlecreekbio.com/

Last Round

Debt

Feb 25, 2025

Est. Valuation

$63.3M

Total Funding Raised

$272.9M

Company Overview

Castle Creek Biosciences is a biotechnology company that develops personalized cell and gene therapies aimed at addressing the root causes of rare skin and connective tissue diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyfibroblast-based therapyrare diseasedermatological diseaseautologous cell therapybiotechlocalized gene therapyconnective tissue diseaseclinical-stage biotechepidermolysis bullosalocalized sclerodermaregenerative medicineex vivo gene therapyorphan drugcell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Castle Creek Biosciences Comparables

Compare Castle Creek Biosciences with similar companies based on industry and business-model similarity.

Castle Creek Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Abeona Therapeutics Inc.
81%
Wings Therapeutics
81%
Krystal Biotech, Inc.
79%

Castle Creek Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtFeb 25, 2025
VC RoundMay 25, 2022
Convertible DebtJun 28, 2021
Series CMar 25, 2020
DebtMar 25, 2020
M&A
Dec 16, 2019

Key People

Founding team and executive leadership

Mayo Pujols

Chief Operating Officer

Executive Team

Castle Creek Biosciences Investors

Notable investors and investment history

Castle Creek Biosciences investors
InvestorRounds
Ligand PharmaceuticalsDebt
EB Research PartnershipPrivate Placement
Fidelity Management & Research CompanyVC Round, Series B, Series C, Convertible Debt
Paragon BiosciencesDebt, VC Round, Series B, Series C
Horizon Technology Finance CorporationDebt
Valor Equity PartnersDebt, VC Round, Series B, Series C
Third SecuritySeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 24, 2026

    Lead candidate for dystrophic epidermolysis bullosa (DEB) enters pivotal trial.

  • Apr 1, 2025

    Lead candidate for DEB moves to pivotal Phase 3 trial, nearing BLA filing.

Castle Creek Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Castle Creek Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Castle Creek Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersExton, Pennsylvania
Employee Range29
Year Founded2018
Last FundingFeb 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.